Impact of topotecan-based chemotherapy on the immune system of advanced ovarian cancer patients: an immunophenotypic study.

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Impact of topotecan-based chemotherapy on the immune system of advanced ovarian cancer patients: an immunophenotypic study.

Oncology reports - 1 Jan 2000

Ferrari Silvia, Rovati Bianca, Cucca Lucia, Scarabelli Claudio, Presti Mauro, Beccaria Cristina, Collovà Elena, Porta Camillo, Danova Marco

Abstract excerpt

The effects of topotecan-based chemotherapy (CT) on peripheral blood lymphocyte (PBL) subsets were evaluated in ovarian cancer patients. Fourteen patients with epithelial ovarian cancer, at the diagnosis or relapsed after platinum-based CT, were treated with: a) topotecan in association with carboplatin and taxanes as first line CT; b) topotecan alone or c) topotecan in association with carboplatin both as second...

Topics

Adult
Aged
Antineoplastic Agents
Female
Humans
Immune System
Immunologic Memory
Immunophenotyping
Lymphocyte Subsets
Middle Aged
Ovarian Neoplasms
Phenotype
Recurrence
Time Factors

Source

Open in PubMed

Identifiers

PMID: 12168081

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Topotecan